Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biote (BTMD) Gains from Sales and Divestitures (2022 - 2025)

Biote (BTMD) has 4 years of Gains from Sales and Divestitures data on record, last reported at $24039.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures fell 94.6% year-over-year to $24039.0; the TTM value through Sep 2025 reached $24039.0, down 94.6%, while the annual FY2024 figure was $444783.0, 64.43% down from the prior year.
  • Gains from Sales and Divestitures reached $24039.0 in Q3 2025 per BTMD's latest filing, roughly flat from $24039.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $2.1 million in Q4 2022 and bottomed at $24039.0 in Q2 2025.
  • Average Gains from Sales and Divestitures over 4 years is $644385.0, with a median of $444783.0 recorded in 2024.
  • Peak YoY movement for Gains from Sales and Divestitures: increased 25.68% in 2023, then crashed 94.6% in 2025.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $2.1 million in 2022, then tumbled by 39.11% to $1.3 million in 2023, then crashed by 64.43% to $444783.0 in 2024, then plummeted by 94.6% to $24039.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $24039.0 in Q3 2025, $24039.0 in Q2 2025, and $444783.0 in Q4 2024.